Evidence map›Paper›PMID 41132461›Full record

ReviewMissouri medicine

Recent Advances in Rheumatology.

Kent Kwas Huston

Abstract readReview
In one paragraph

Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kent Kwas HustonRheumatologist with Kansas City Physician Partners, Kansas City, Missouri, USA, and a Clinical Associate Professor of Medicine at the University of Missouri-Kansas City, Kansas City, Missouri, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are too many topics for this article to represent a comprehensive and thorough review of rheumatology. Instead, this paper will focus on advances which would be of interest to a general medical audience. Highlighted are the more commonly encountered rheumatic diseases as well as uncommon disorders that are of significant interest as they expand our understanding of biologic mechanisms of disease. We will take a tour from rheumatoid arthritis to a fascinating new entity called VEXAS. The purpose of this review is to broaden knowledge of mechanistic and therapeutic advances in rheumatology and foster a greater appreciation of current management principles related to autoimmune rheumatic disease.

Indexed as

Rheumatic DiseasesRheumatologyArthritis, RheumatoidAutoimmune DiseasesHumans

Identifiers

PMID41132461
PMCPMC12543342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.